inhibitor

(redirected from PDE inhibitor)
Also found in: Dictionary, Medical, Legal, Encyclopedia.
Related to PDE inhibitor: phosphodiesterase type 5 inhibitors, PDE5
Graphic Thesaurus  🔍
Display ON
Animation ON
Legend
Synonym
Antonym
Related
  • noun

Antonyms for inhibitor

a substance that retards or stops an activity

References in periodicals archive ?
Get an up-to-date perspective on PDE inhibitor targets with a systematic review of each PDE family.
The patent covers compounds combining a class of PDE inhibitors and specific NO donors for the treatment of MED.
Bernd Kastler, CEO of elbion, said: "This collaboration underlines the high quality of elbion's science, particularly our expertise in the highly promising field of PDE inhibitors.
NO data are available on the prolonged use of PDE inhibitors in adult critically ill patients, although ample literature is now available on chronically ill subjects with pulmonary hypertension (6).
Powerful and unexpected synergistic interactions of A2A Agonist and PDE Inhibitors as potential adjunctive therapy in the treatment of multiple myeloma and other B-cell malignancies were published in BLOOD, The Journal of the American Society of Hematology, and highlighted at the American Association for Cancer Research 2010 annual meeting.
It is notable that this activity is comparable to that of zaprinast, which is one of the few cGMP-specific PDE inhibitors (Sugita and Black, 1998).
Vivien Mak, Vice President of Research at Cellegy, commented, "Over the past two weeks, Cellegy has been issued two important United States patents (covering the use of PDE inhibitors and potassium channel openers) that result from our ongoing efforts to develop products for the treatment of fissures and hemorrhoids.
1182/blood-2009-11-252668, CombinatoRx researchers, in collaboration with the Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, demonstrate the powerful and unexpected synergistic interactions of A2A Agonist and PDE Inhibitors as potential adjunctive therapy to glucocorticoid (GC) containing regimens in the treatment of multiple myeloma (MM) and other B-cell malignancies.
Concomitant administration with phosphodiesterase (PDE) inhibitors, including specific PDE-5 inhibitors (such as sildenafil, tadalafil, or vardenafil) or nonspecific PDE inhibitors (such as dipyridamole or theophylline).
The PDE inhibitors covered in the present patent include those which decrease or abolish the activity of PDE 3, PDE 4 and PDE 5.
PDE inhibitors are an important class of pharmaceutical compounds with highly distinct efficacy and safety profiles depending on the specific PDE target.